Brain Cancer Clinical Trials in Pittsburgh

Showing 41-60 of 181 trials

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933

This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas

NeoplasmsHigh Grade GliomaGlioblastoma Multiforme+5 more

Pediatric Brain Tumor ConsortiumStarted Sep 2025

Aurora, Colorado, United States • New York, New York, United States • Pittsburgh, Pennsylvania, United States +2 more locations

Not Yet RecruitingPhase 2< 1 mile

A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients

NCT06907485

This clinical trial focuses on pediatric patients aged 2 up to 18 years of age with a new or recurrent pediatric brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal. 5-aminolevulinic acid (5-ALA) is FDA-approved for improving brain tumor visualization in adults during surgery through fluorescence, enabling more complete removal of the tumor. This study aims to evaluate the feasibility of administering 5-ALA to pediatric brain tumor patients and to assess the quality of tumor fluorescence during surgery in this patient population. For the clinical trial, the patient will orally ingest 5-ALA 6 to 12 hours before brain surgery. All study participants will be provided standard medical care for removal of the brain tumor. All children enrolled in the study will be closely monitored prior to, during, and after surgery to ensure there are no reactions to the study drug. 5-ALA can make the patient more sensitive to sunlight and direct indoor lighting, referred to as photosensitivity, and can cause a sunburn-type reaction. It is for this reason that patients will be kept in subdued light conditions for 48 hours following surgery. Study participation starts once the patient is enrolled in the study until 6-month post-surgery.

Pediatric Brain Tumor

Costas Hadjipanayis20 participantsStarted Aug 2026

Chicago, Illinois, United States • Pittsburgh, Pennsylvania, United States

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients

Brain Cancer Trials in Other Cities

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

DAY101 In Gliomas and Other Tumors

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Neuronal and Network Mechanisms of Electrocortical Stimulation

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

AB154 Combined With AB122 for Recurrent Glioblastoma

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

Other Conditions in Pittsburgh